Efficacy and Safety of TenoMiR in Lateral Epicondylitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Tennis Elbow

In brief

This study is testing a drug called TenoMiR that is being developed for the treatment of tennis elbow (lateral epicondylitis). The study drug is a new compound that works by improving the quality of the collagen which helps repair damage to the elbow. The study drug is being developed in the hope of providing a more reliable treatment than those currently available and can be given at the time of first diagnosis, so that recovery can begin as soon as possible. The study drug has been tested in humans in an earlier study, and appeared to be safe and well-tolerated. This study aims to test the study drug in a larger number of participants.

Key facts

Study ID

NCT06192927

Run by

Causeway Therapeutics

People needed

123

Starts

2024-04-10

Expected to finish

2025-06-12

Last updated by the study team

2025-08-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must meet all of the following inclusion criteria.
• Subject has a clinical diagnosis of lateral epicondylitis.
• Aside from lateral epicondylitis, the subject is otherwise healthy as determined by a responsible physician, based on medical history, physical examinations, concomitant medication, vital signs, 12-lead ECGs and clinical laboratory evaluations. Laboratory values may be retested once at the discretion of the Investigator.
• Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion (as confirmed by tenderness at lateral epicondyle and positive pick up back of chair sign).
• Subject's symptoms have persisted for at least 6 weeks to 9 months, despite conservative treatment that includes 1 or combinations of:
• Physical therapy
• Splinting
• NSAIDs

You may not qualify if…

• Subjects with any of the following will be excluded from study participation:
• Subject has undergone previous corticosteroid injection therapy to the affected elbow in less than 6 months prior to enrolment.
• Subjects unwilling or unable to discontinue use of pain medication (opiate or NSAID) from at least 1 week prior to Investigational Medicinal Product (IMP) administration.
• Subject has received previous Platelet-Rich Plasma (PRP) injection to the affected elbow.
• Subject uses or has recent use of medications known to affect the skeleton (e.g., glucocorticoid usage >5 mg/day, fluoroquinolone antibiotics).
• Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis.

Where it is running

• Stanford Medicine — Redwood City, California, United States
• Hospital for Special Surgery — New York, New York, United States
• NYU Langone Health — New York, New York, United States
• Panthera Biopartners — Enfield, United Kingdom
• Panthera Biopartners — Glasgow, United Kingdom
• Glasgow Clinical Research Facility — Glasgow, United Kingdom
• Panthera Biopartners — Preston, United Kingdom
• Panthera Biopartners — Rochdale, United Kingdom
• Panthera Biopartners — Sheffield, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.